Baylor College of Medicine, Menninger Department of Psychiatry & Behavioral Sciences, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States of America.
PLoS One. 2012;7(11):e47702. doi: 10.1371/journal.pone.0047702. Epub 2012 Nov 8.
Clinical trials indicate that disulfiram (250 mg/d) reduces cocaine use, though one study found that treatment with lower doses of disulfiram (62.5 and 125 mg/d) increased cocaine use. We conducted the present study to better understand how disulfiram alters the reinforcing effects of cocaine in cocaine users.
Seventeen non-treatment seeking, cocaine-dependent volunteers participated in this double-blind, placebo-controlled, laboratory-based study. A cross-over design was utilized in which participants received placebo in one phase and disulfiram (250 mg/d) in the other. Following three days of study medication participants completed two choice sessions. In one they made 10 choices between receiving an intravenous infusion of saline or money that increased in value (US$ 0.05-16) and in the other cocaine (20 mg) or money.
Participants chose cocaine more than saline under both disulfiram and placebo conditions (p<0.05). Unexpectedly, disulfiram increased both the number of cocaine and saline infusion choices (p<0.05). We next examined the relationship between disulfiram dose and cocaine choices. Disulfiram dose (mg/kg bodyweight) was negatively correlated with number of choices for cocaine (p<0.05). Disulfiram also enhanced cocaine-induced increases in cardiovascular measures (p's<0.05-0.01).
Disulfiram's impact on the reinforcing effects of cocaine depends on dose relative to body weight. Our results suggest that the use of weight-based medication doses would produce more reliable effects, consistent with weight-based dosing used in pediatrics and in preclinical research.
Clinicaltrials.gov NCT00729300.
临床试验表明,双硫仑(250 毫克/天)可减少可卡因的使用,但一项研究发现,使用较低剂量的双硫仑(62.5 和 125 毫克/天)会增加可卡因的使用。我们进行了这项研究,以更好地了解双硫仑如何改变可卡因使用者对可卡因的强化作用。
17 名非治疗性寻求、可卡因依赖的志愿者参加了这项双盲、安慰剂对照、基于实验室的研究。采用交叉设计,参与者在一个阶段接受安慰剂,在另一个阶段接受双硫仑(250 毫克/天)。在研究药物的三天后,参与者完成了两个选择阶段。在一个阶段,他们在接受静脉内输注生理盐水或金钱(价值增加 0.05-16 美元)之间做出 10 次选择,在另一个阶段选择可卡因(20 毫克)或金钱。
参与者在双硫仑和安慰剂条件下都选择可卡因多于生理盐水(p<0.05)。出乎意料的是,双硫仑增加了可卡因和生理盐水输注的选择数量(p<0.05)。我们接下来检查了双硫仑剂量与可卡因选择之间的关系。双硫仑剂量(mg/kg 体重)与可卡因选择数量呈负相关(p<0.05)。双硫仑还增强了可卡因引起的心血管措施的增加(p's<0.05-0.01)。
双硫仑对可卡因强化作用的影响取决于剂量与体重的关系。我们的结果表明,使用基于体重的药物剂量会产生更可靠的效果,与儿科和临床前研究中使用的基于体重的剂量一致。
Clinicaltrials.gov NCT00729300。